Chris Howerton analyst

Currently out of the existing stock ratings of Chris Howerton, 105 are a BUY (77.21%), 27 are a HOLD (19.85%), 4 are a SELL (2.94%).

Chris Howerton

Work Performance Price Targets & Ratings Chart

Analyst Chris Howerton, currently employed carries an average stock price target met ratio of 50.98% that have a potential upside of 31.9% achieved within 147 days. Previously, Chris Howerton worked at JEFFERIES.

Chris Howerton’s has documented 279 price targets and ratings displayed on 41 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on APLS, Apellis Pharmaceuticals at 18-Jan-2024.

Wall Street Analyst Chris Howerton

Analyst best performing recommendations are on PSTI (PLURISTEM).
The best stock recommendation documented was for PSTI (PLURISTEM) at 12/10/2020. The price target of $6 was fulfilled within 1 day with a profit of $0.22 (3.54%) receiving and performance score of 35.37.

Average potential price target upside

ACAD ACADIA Pharmaceuticals AMTI Applied Molecular Transport  AXSM Axsome Therapeutics BTAI BioXcel Therapeutics GMTX Gemini Therapeutics IMMU Immunomedics KRTX Karuna Therapeutics MCRB Seres Therapeutics PSTI Pluristem TGTX TG Therapeutics TXMD TherapeuticsMD VERU Veru VNDA Vanda Pharmaceuticals CARA Cara Therapeutic SPPI Spectrum Pharmaceuticals APLS Apellis Pharmaceuticals ARDX Ardelyx ARNA Arena Pharmaceuticals AVDL Avadel Pharmaceuticals PLC CLDX Celldex Therapeutics EVLO Evelo Biosciences HRMY Harmony Biosciences Holdings IGMS IGM Biosciences MEIP MEI Pharma AVTX Avalo Therapeutics FNCH Finch Therapeutics Group ISEE IVERIC bio LABP Landos Biopharma PNT POINT Biopharma Global TCRT Alaunos Therapeutics ZIOP ZIOPHARM Oncology PRVB Provention Bio KDMN Kadmon Holdings CGEN Compugen CORT Corcept Therapeutics orporated IOBT IO Biotech LQDA Liquidia Technologies MIST Milestone Pharmaceuticals PTGX Protagonist Therapeutics URGN UroGen Pharma Ltd VRDN Viridian Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$27

$10.13 (60.05%)

$27

1 months 17 days ago
(07-Nov-2024)

8/22 (36.36%)

$9.79 (56.89%)

119

Buy

$28

$11.13 (65.98%)

$28

1 months 17 days ago
(07-Nov-2024)

0/4 (0%)

$10.79 (62.70%)

Hold

2 months 14 days ago
(10-Oct-2024)

11/14 (78.57%)

$9.98 (39.89%)

141

Buy

$23

$6.13 (36.34%)

$30

4 months 16 days ago
(08-Aug-2024)

0/3 (0%)

$7.28 (46.31%)

Buy

$20

$3.13 (18.55%)

$28

4 months 17 days ago
(07-Aug-2024)

16/21 (76.19%)

$4.83 (31.84%)

184

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Chris Howerton?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?